Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
68
KNSA Quote, Financials, Valuation and Earnings
Last price:
$42.55
Seasonality move
:
0.24%
Day range:
$42.29 - $42.99
52-week range:
$17.82 - $44.42
Dividend yield:
0%
P/E ratio:
94.78x
P/S ratio:
5.44x
P/B ratio:
6.02x
Volume:
153.8K
Avg. volume:
389.9K
1-year change:
113.09%
Market cap:
$3.2B
Revenue:
$423.2M
EPS (TTM):
$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$167.4M | $0.37 | 60.47% | -62.86% | $54.71 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
AKAN
Akanda Corp.
|
-- | -- | -- | -- | -- |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
LIVN
LivaNova Plc
|
$342.3M | $0.92 | 9.77% | -20.8% | $70.64 |
|
NVCR
NovoCure Ltd.
|
$158.9M | -$0.42 | 4.75% | -35.35% | $24.79 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$42.49 | $54.71 | $3.2B | 94.78x | $0.00 | 0% | 5.44x |
|
ADMA
ADMA Biologics, Inc.
|
$19.53 | $25.67 | $4.6B | 22.93x | $0.00 | 0% | 9.83x |
|
AKAN
Akanda Corp.
|
$0.50 | -- | $362.5K | -- | $0.00 | 0% | 0.93x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
LIVN
LivaNova Plc
|
$63.08 | $70.64 | $3.4B | 38.16x | $0.00 | 0% | 2.56x |
|
NVCR
NovoCure Ltd.
|
$13.44 | $24.79 | $1.5B | -- | $0.00 | 0% | 2.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
1.78% | -0.243 | 0.33% | 3.27x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
AKAN
Akanda Corp.
|
7.2% | 1.308 | 5.92% | 1.17x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
LIVN
LivaNova Plc
|
29.6% | 1.882 | 17.01% | 1.05x |
|
NVCR
NovoCure Ltd.
|
70.04% | -1.015 | 55.15% | 1.44x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$97.3M | $24M | 7.44% | 7.6% | 13.28% | $33M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
AKAN
Akanda Corp.
|
-- | -- | -276.52% | -389.63% | -- | -- |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
LIVN
LivaNova Plc
|
$244.9M | $56.6M | -12.15% | -18.29% | 15.83% | $62.2M |
|
NVCR
NovoCure Ltd.
|
$122.5M | -$36M | -16.67% | -50.08% | -21.54% | $14.9M |
Kiniksa Pharmaceuticals International Plc vs. Competitors
-
Which has Higher Returns KNSA or ADMA?
ADMA Biologics, Inc. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of 27.14%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About KNSA or ADMA?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.71, signalling upside risk potential of 28.77%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 31.69%. Given that ADMA Biologics, Inc. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe ADMA Biologics, Inc. is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is KNSA or ADMA More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock KNSA or ADMA?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or ADMA?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than ADMA Biologics, Inc. quarterly revenues of $134.2M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 94.78x while ADMA Biologics, Inc.'s PE ratio is 22.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.44x versus 9.83x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.44x 94.78x $180.9M $18.4M ADMAADMA Biologics, Inc.9.83x 22.93x $134.2M $36.4M
-
Which has Higher Returns KNSA or AKAN?
Akanda Corp. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of --. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat Akanda Corp.'s return on equity of -389.63%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M AKANAkanda Corp.-- -- $4.9M -
What do Analysts Say About KNSA or AKAN?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.71, signalling upside risk potential of 28.77%. On the other hand Akanda Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than Akanda Corp., analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than Akanda Corp..
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 AKANAkanda Corp.0 0 0 -
Is KNSA or AKAN More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison Akanda Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KNSA or AKAN?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akanda Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. Akanda Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or AKAN?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than Akanda Corp. quarterly revenues of --. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is higher than Akanda Corp.'s net income of --. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 94.78x while Akanda Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.44x versus 0.93x for Akanda Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.44x 94.78x $180.9M $18.4M AKANAkanda Corp.0.93x -- -- --
-
Which has Higher Returns KNSA or CRMD?
CorMedix, Inc. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of 49.9%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About KNSA or CRMD?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.71, signalling upside risk potential of 28.77%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that CorMedix, Inc. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe CorMedix, Inc. is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 CRMDCorMedix, Inc.4 0 0 -
Is KNSA or CRMD More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock KNSA or CRMD?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or CRMD?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 94.78x while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.44x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.44x 94.78x $180.9M $18.4M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns KNSA or LIVN?
LivaNova Plc has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of 7.49%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat LivaNova Plc's return on equity of -18.29%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M LIVNLivaNova Plc68.44% $0.49 $1.6B -
What do Analysts Say About KNSA or LIVN?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.71, signalling upside risk potential of 28.77%. On the other hand LivaNova Plc has an analysts' consensus of $70.64 which suggests that it could grow by 11.98%. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than LivaNova Plc, analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 LIVNLivaNova Plc6 2 0 -
Is KNSA or LIVN More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison LivaNova Plc has a beta of 1.020, suggesting its more volatile than the S&P 500 by 2.023%.
-
Which is a Better Dividend Stock KNSA or LIVN?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LivaNova Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. LivaNova Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or LIVN?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are smaller than LivaNova Plc quarterly revenues of $357.8M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is lower than LivaNova Plc's net income of $26.8M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 94.78x while LivaNova Plc's PE ratio is 38.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.44x versus 2.56x for LivaNova Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.44x 94.78x $180.9M $18.4M LIVNLivaNova Plc2.56x 38.16x $357.8M $26.8M
-
Which has Higher Returns KNSA or NVCR?
NovoCure Ltd. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of -22.29%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat NovoCure Ltd.'s return on equity of -50.08%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M NVCRNovoCure Ltd.73.25% -$0.33 $1.1B -
What do Analysts Say About KNSA or NVCR?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.71, signalling upside risk potential of 28.77%. On the other hand NovoCure Ltd. has an analysts' consensus of $24.79 which suggests that it could grow by 84.42%. Given that NovoCure Ltd. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe NovoCure Ltd. is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 NVCRNovoCure Ltd.4 2 0 -
Is KNSA or NVCR More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison NovoCure Ltd. has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.463%.
-
Which is a Better Dividend Stock KNSA or NVCR?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovoCure Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. NovoCure Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or NVCR?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than NovoCure Ltd. quarterly revenues of $167.2M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is higher than NovoCure Ltd.'s net income of -$37.3M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 94.78x while NovoCure Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.44x versus 2.31x for NovoCure Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.44x 94.78x $180.9M $18.4M NVCRNovoCure Ltd.2.31x -- $167.2M -$37.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
